Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...

This partnership aims to explore ivonescimab's potential in combination with innovative ADCs in multiple solid tumor types. Top-line data for the HARMONi Phase III trial will include progression ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Summit Therapeutics Inc (SMMT) reports a robust cash reserve and debt-free status, while advancing key clinical trials and ...

Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...